Clinical trials: SARS-COV-2 Infections
COVID-19
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19
This is a phase 2 randomized, double-blind clinical trial testing an anti-SARS-CoV-2 COVID-19 vaccine (AV-COVID-19) made on site using PT AIVITA Biomedika Indonesia's vaccine-enabling kit for the prevention of COVID-19 infection.
- Trial name
- NCT05007496
- Testing
- AV-COVID-19
- Where
- Indonesia
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
Healthy
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19.
- Trial name
- NCT05580003
- Testing
- PF-07817883, Midazolam, Moxifloxacin
- Where
- 2 sites in United States, Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID19
Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19
This is a randomized, sham controlled, dose finding study of the EmitBio RD-X19 device in individuals with symptomatic COVID-19 in the outpatient setting.
- Trial name
- NCT04966013
- Testing
- RD-X19
- Where
- 9 sites in United States
- Volunteers
- 216 people
- Sponsor
- EmitBio Inc.
COVID 19
Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Study to Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
- Trial name
- NCT04561076
- Testing
- HLX70
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hengenix Biotech Inc
Healthy Volunteers
iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects
This is a Phase 1, double-blind, randomized, placebo-controlled study to investigate single and multiple intravenous infusions of improved cell-permeable nuclear import inhibitor (iCP NI) in healthy subjects.
- Trial name
- NCT05740280
- Testing
- iCP-NI
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Cellivery Therapeutics, Inc.
COVID - 19
A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults
A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years
- Trial name
- NCT07728396
- Testing
- GC4006A, Normal Saline
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
COVID-19, Coronavirus Disease 2019
SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study
SARS-CoV-2 Nucleic Acid Detection Kit is an In Vitro Diagnostic (IVD) medical device intended for RNA detection of SARS-CoV-2 in human specimens using multiplex real-time polymerase chain reaction (RT-PCR) technology.
- Conditions
- COVID-19, Coronavirus Disease 2019, COVID-19 Pandemic, Diagnoses Disease
- Trial name
- CPS CW008 (NCT05492227)
- Testing
- Left-overs
- Where
- Spain
- Volunteers
- 607 people, healthy volunteers welcome
- Sponsor
- TransGen Biotech Co., LTD
Covid19, Novel Coronavirus Pneumonia
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
Novel coronavirus pneumonia (NCP) and acute respiratory distress syndrome (ARDS) are both associated with the prevailing upper respiratory tract infections caused by the RNA-containing SARS-CoV2 virus of the genius…
- Conditions
- Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- ARDOXSO (NCT04798716)
- Testing
- MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- AVEM HealthCare
COVID-19
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo…
- Trial name
- NCT04377711
- Testing
- Ciclesonide
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Covis Pharma S.à.r.l.
COVID-19
A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers
The purpose of this study is to assess the safety, tolerability, and immunization of Nanocovax in healthy volunteers.
- Trial name
- NCT04683484
- Testing
- Nanocovax
- Where
- Vietnam
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
COVID-19
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase Ⅱ clinical trial to evaluate efficacy and safety of Pyramax in mild to moderate COVID-19 patients.
- Trial name
- NCT04475107
- Testing
- Pyronaridine-Artesunate
- Where
- 13 sites in South Korea
- Volunteers
- 113 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Post COVID-19 Condition, Post COVID-19 Condition (PCC)
Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients
This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without…
- Conditions
- Post COVID-19 Condition, Post COVID-19 Condition (PCC), Post COVID-19, Post COVID-19 Syndrome
- Trial name
- HydroCoVitalB (NCT07110714)
- Testing
- Cold water hydrotherapy
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Eggensberger OHG
Non-Small Cell Lung Cancer, Metastatic Melanoma
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
The aims of this Study were to determine: How much of the Study Drug (bemcentinib) ends up in urine and faeces How much of the Study Drug and its breakdown products get into the bloodstream The breakdown products (metabolites) of…
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- 8479217 (NCT06469138)
- Testing
- Bemcentinib
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
Covid19
A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects
This study is an adaptive Phase III randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of Proxalutamide (GT0918) in hospitalized adults diagnosed with COVID-19.
- Trial name
- NCT05009732
- Testing
- GT0918, Standard of care
- Where
- 30 sites in United States, China and 3 more
- Volunteers
- 139 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
COVID-19
Zofin to Treat COVID-19 Long Haulers
The purpose of this study is to assess the safety and potential efficacy of Zofin administered intravenously in subjects experiencing prolonged symptoms (> 6 weeks and < 24 months) of COVID-19.
- Trial name
- NCT05228899
- Testing
- Zofin
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ZEO ScientifiX, Inc.
Relapsing Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
This study aimed to understand whether patients with relapsing multiple sclerosis (RMS) can mount an immune response to SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation…
- Trial name
- KYRIOS (NCT04869358)
- Testing
- Ofatumumab
- Where
- 6 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine
Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O, Ad5-nCoV/O-IH or mRNA-based…
- Trial name
- NCT05442684
- Testing
- Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation, mRNA-based COVID-19 vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
COVID-19
Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)
This is a multicenter designed Phase III clinical trial. About 10000 participants plan to be enrolled.The objectives of this study are to evaluate the efficacy, safety and immunogenicity of the recombinant two-component COVID-19…
- Trial name
- NCT05398848
- Testing
- Recombinant two-component COVID-19 vaccine (CHO cell)
- Where
- 11 sites in Nepal, Russia
- Volunteers
- 7,623 people, healthy volunteers welcome
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
Pneumonia
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
Part 1 of this trial enrolled 30 patients to receive Auxora (formerly CM4620) in a 2:1 randomized, open label trial of patients with severe and critical COVID-19 pneumonia.
- Trial name
- NCT04345614
- Testing
- Auxora (Part 1), Standard of Care (Part 1), Auxora (Part 2)
- Where
- 17 sites in United States
- Volunteers
- 314 people
- Sponsor
- CalciMedica, Inc.
COVID-19
Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents
This study is a global multi-center , case-driven, randomized, double-blinded, and placebo-controlled phase Ⅲ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04992260
- Testing
- Inactivated COVID-19 Vaccine, Controlled vaccine
- Where
- 38 sites in Chile, Malaysia and 2 more
- Volunteers
- 11,349 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.